AOAlex J. O'Neill

Alex J. O'Neill

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Alex J. O'Neill has a total of 248 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    AntibioticDB: An Updated and Improved Open-Access Database for the Antibacterial Research and Development Community

    by Luiza H. Galarion, Alan Hennessy, Simon D. Harding, Jane F. Armstrong, Astrid Pentz-Murr, Jamie A. Davies, Alex J. O’NEill, Laura J. V. Piddock

    AntibioticDB (https://www.antibioticdb.com/), originally established in 2017 and since 2021 led by the Global Antibiotic Research & Development Partnership (GARDP), is a freely available database of antibacterial agents to facilitate research and development of new antibacterial therapeutics. Here, we describe a new release of AntibioticDB that has been significantly expanded and updated with the aid of user feedback and which offers additional functionality through a redesigned web portal. Improvements include reciprocal integration with the IUPHAR/BPS Guide to Pharmacology (https://www.guidetopharmacology.org), capturing of compound structure information in the form of standard chemical identifiers (canonical and isomeric SMILES, InChI, and InChI Key), chemical 2D structure images, and harmonizing terminology to optimize database searching. Ongoing curation efforts have increased the number of individual entries to >3,500, a process driven mostly by a significant expansion of historical natural product antibiotics that were previously under-represented in the database. The database is continuously updated by mining the published literature and capturing newly discovered antibacterial compounds as they are reported, making AntibioticDB the most complete global resource on antibacterial agents.


  • Open Access

    Nature of bacitracin resistance in Staphylococcus aureus

    by Merianne Mohamad, Mollie M. Hurst, Elham Elkrewi, Christopher P. Randall, Alex J. O’nEill

    Bacitracin is employed for topical treatment of staphylococcal infection, though information is lacking regarding the nature of resistance to this antibiotic in the staphylococci. Here we examined bacitracin resistance in a large collection ( n = 1,470) of multidrug-resistant isolates of Staphylococcus aureus . Susceptibility testing of the entire collection revealed a broad range of bacitracin minimum inhibitory concentrations (MICs) (from 32 to >4,096 µg/mL) and allowed us to define a tentative epidemiological cut-off value (TECOFF) (apparent upper end of the wild-type distribution in terms of bacitracin susceptibility) of 256 µg/mL. On the basis of this TECOFF, 101 strains (6.8% of the total) for which bacitracin had an MIC of ≥512 µg/mL were considered resistant. Bacitracin resistance was found across multiple sequence types (STs), though over half the resistant strains belonged to the ST8:USA300 lineage. In nearly all bacitracin-resistant strains (99 of 101), whole genome sequence analysis identified operons similar to the bcrABD operon that confers bacitracin resistance in Enterococcus faecalis ; 3 strains carried an operon [ bcrAB (ISL3) D ] closely related to the latter (~90% identity in the encoded resistance proteins), while 96 strains harbored a more distantly related operon (bcrEFH . Molecular cloning experiments confirmed the ability of both bcr operons to confer bacitracin resistance in S. aureus . Both bcrAB (ISL3) D and bcrEFH reside on IS 6 -flanked pseudo-compound transposons on multidrug resistance plasmids, highlighting their potential to spread and become more widely disseminated among staphylococci.


  • Open Access

    Carrier-mediated transport as a common route of antibiotic ingress into bacteria

    by Justin E. Clarke, Luiza H. Galarion, Abdulmenem A. Almadani, Christopher N. A. Smith, John D. Wright, Stuart L. Warriner, Alex J. O'NEill

    Among the most significant challenges in antibacterial discovery is achieving delivery of small molecule inhibitors across the bacterial membrane(s) to reach their intracellular targets. It is considered axiomatic that the typical route for antibiotics across the cytoplasmic membrane (CM) involves diffusion directly through the lipid bilayer, though this concept has not translated into actionable information for rationally achieving ingress of inhibitors into bacteria. Here, using antibiotic accumulation measurements in bacteria inactivated for individual or multiple CM transporters, we provide evidence that a diverse range of established antibiotic classes are transported across the CM by hitch-hiking on carrier proteins. The chemical similarity between some antibiotic classes and the native substrate(s) of the importer they share provides a molecular logic for drug transport. Our results indicate that carrier-mediated uptake is a common route of antibiotic entry into bacteria and highlight the value of metabolite mimicry in designing new antibacterial drugs. IMPORTANCE: Increasing antibiotic resistance among pathogenic bacteria is undermining our ability to treat infection, and new antibacterial drugs are urgently needed to address the problem. One of the most significant challenges in antibacterial discovery is achieving delivery of inhibitors across the bacterial membrane(s) to reach their intracellular targets, reflecting the lack of a granular understanding about how antibiotics enter bacteria. Here, we provide evidence that a common route for established antibiotics into bacteria involves uptake by membrane transport proteins. Our findings thereby offer a clear route forward for antibacterial discovery: mimicry of the natural substrates of transporter proteins to achieve carrier-mediated uptake of inhibitors into the bacterial cell.


  • Open Access

    The native ABC-F proteins of Staphylococcus aureus do not contribute to intrinsic resistance against ribosome-targeting antibacterial drugs

    by Luiza H Galarion, James Trigwell, Merianne Mohamad, Jose A Nakamoto, Justin E Clarke, Gemma C Atkinson, Alex J O’nEill

    Antibiotic resistance ATP-binding cassette F (ARE ABC-F) proteins are a major cause of acquired resistance to antibacterial drugs that target protein synthesis.1 These proteins bind to the ribosome to drive antibiotic release, a mechanism known as target protection,2 and thereby mediate resistance to diverse drug classes that act on the 50S subunit (lincosamides, macrolides, oxazolidinones, phenicols, pleuromutilins and streptogramins).1


  • Open Access

    An Engineered Escherichia coli Community for Studying Quorum Sensing

    by Yuwei Li, Justin E. Clarke, Alex J. O’neill, Francisco M. Goycoolea, James Smith

    In bacterial communities, quorum sensing (QS) is a process mediated via chemical signalling that individuals use to coordinate their collective phenotypes. It is closely associated with pathogenic traits such as virulence factor production and antibiotic resistance. In their natural habitats, bacteria live in small niches, forming intricate consortia, where the role of QS is little understood. This work aims to construct a tuneable, trackable, and reconfigurable model bacterial community for studying QS. To this end, three Escherichia coli fluorescent reporter strains were constructed based on the paradigm LuxI/LuxR QS system. The strains recreate the three major aspects of QS response: sensing (S), autoinducer production (P), and regulation (R). We found that the response of the S strain as a function of the N-(3-oxohexanoyl)-L-homoserine lactone (OHHL) concentration did not saturate and exhibited a concentration-dependent response (in the range 10−7 to 10−4 M). The P strain produced OHHL and showed the ability to activate the S response, while the R strain showed the ability to attenuate the response due to the expression of the lactonase AiiA. Monitoring the fluorescent signals of the strains permits tracking the activation and attenuation activities of the LuxI/LuxR QS system. Future studies can now also benefit from this straightforward subcloning strategy to study other QS systems.


  • Open Access

    Resistance to antibacterial antifolates in multidrug-resistant Staphylococcus aureus: prevalence estimates and genetic basis

    by Louise Kime, Tina Waring, Merianne Mohamad, Benjamin F Mann, Alex J O’nEill

    Antibacterial antifolate drugs might have a wider role in the management of staphylococcal infection. One factor that could potentially limit their use in this context is pre-existing resistance. Here we explored the prevalence and genetic basis for resistance to these drugs in a large collection (n = 1470) of multidrug-resistant (MDR) Staphylococcus aureus. Strains were subjected to susceptibility testing to detect resistance to trimethoprim, sulfamethoxazole, co-trimoxazole and the investigational drug, iclaprim. Whole-genome sequences were interrogated to establish the genetic basis for resistance. According to CLSI breakpoints, 15.2% of the strains were resistant to trimethoprim, 5.2% to sulfamethoxazole and 4.1% to co-trimoxazole. Using the proposed breakpoint for iclaprim, 89% of the trimethoprim-resistant strains exhibited non-susceptibility to this agent. Sulfamethozaxole resistance was exclusively the result of mutation in the drug target (dihydropteroate synthase). Resistance to trimethoprim and iclaprim also resulted from mutation in the target (dihydrofolate reductase; DHFR) but was more commonly associated with horizontal acquisition of genes encoding drug-insensitive DHFR proteins. Among the latter, we identified a novel gene (dfrL) encoding a DHFR with ∼35% identity to native and known resistant DHFRs, which was confirmed via molecular cloning to mediate high-level resistance. This study provides a detailed picture of the genotypes underlying staphylococcal resistance to antifolate drugs in clinical use and in development. Prevalence estimates suggest that resistance to the diaminopyrimidines (trimethoprim/iclaprim) is not uncommon among MDR S. aureus, and considerably higher than observed for sulfamethoxazole or co-trimoxazole.


  • Open Access

    An extensively validated whole-cell biosensor for specific, sensitive and high-throughput detection of antibacterial inhibitors targeting cell-wall biosynthesis

    by Luiza H Galarion, Jennifer K Mitchell, Christopher P Randall, Alex J O’nEill

    Whole-cell biosensor strains are powerful tools for antibacterial drug discovery, in principle allowing the identification of inhibitors acting on specific, high-value target pathways. Whilst a variety of biosensors have been described for detecting cell-wall biosynthesis inhibitors (CWBIs), these strains typically lack specificity and/or sensitivity, and have for the most part not been rigorously evaluated as primary screening tools. Here, we describe several Staphylococcus aureus CWBI biosensors and show that specific and sensitive biosensor-based discovery of CWBIs is achievable. Biosensors comprised lacZ reporter fusions with S. aureus promoters (PgltB, PilvD, PmurZ, PoppB, PORF2768, PsgtB) that are subject to up-regulation following inhibition of cell-wall biosynthesis. Induction of biosensors was detected by measuring expression of β-galactosidase using fluorogenic or luminogenic substrates. Three of the six biosensors tested (those based on PgltB, PmurZ, PsgtB) exhibited apparently specific induction of β-galactosidase expression in the presence of CWBIs. Further validation of one of these (PmurZ) using an extensive array of positive and negative control compounds and conditional mutants established that it responded appropriately and uniquely to inhibition of cell-wall biosynthesis. Using this biosensor, we established, validated and deployed a high-throughput assay that identified a potentially novel CWBI from a screen of >9000 natural product extracts. Our extensively validated PmurZ biosensor strain offers specific and sensitive detection of CWBIs, and is well-suited for high-throughput screening; it therefore represents a valuable tool for antibacterial drug discovery.


  • Comment on: Identification of a novel tedizolid resistance mutation in rpoB of MRSA after in vitro serial passage

    by Luiza H Galarion, Justin E Clarke, Harry Schofield, Alex J O’nEill

    A recent JAC article by Shen et al.1 reported that a single amino acid substitution in RNA polymerase can mediate resistance to the oxazolidinone tedizolid and other ribosome-targeting antibiotics in Staphylococcus aureus. Following 10 days’ serial passage of S. aureus N315 in the presence of tedizolid, the authors of that study recovered a mutant (N315-TDZ4) that exhibited tedizolid resistance above the clinical breakpoint. N315-TDZ4 also displayed cross-resistance to several other classes of translation inhibitor that bind the ribosome in close proximity to tedizolid, a phenotype known as PhLOPSA (for resistance to Phenicols, Lincosamides, Oxazolidinones, Pleuromutilins and Streptogramins of group A). WGS of N315-TDZ4 identified a single nucleotide mutation relative to the parent strain: a A1345G change in the rpoB gene, which encodes a N449D amino acid substitution in the β-subunit of RNA polymerase. The authors concluded that this substitution was responsible for the observed PhLOPSA phenotype. We considered this a surprising finding for several reasons. Despite an extensive body of published work that has examined resistance to oxazolidinones and other PhLOPSA classes in laboratory strains and clinical isolates, there has to our knowledge been no previous suggestion that resistance can result from mutational change in RNA polymerase. Indeed, there is no obvious explanation for how genetic alteration of the transcription machinery might mediate resistance to a cross-section of structurally unrelated and mechanistically distinct antibacterial drug classes that act on the ribosome. Furthermore, it is not easy to reconcile the idea that resistance to tedizolid can result from a single point mutation with the observed difficulty of selecting mutants resistant to tedizolid in vitro. Typically, when S. aureus is challenged with an antibacterial drug against which resistance can arise via a single point mutation, resistant mutants are recovered at frequencies of >10−9.2 By contrast, we were unable to detect tedizolid-resistant mutants (frequency of −11) upon plating concentrated cultures of S. aureus N315 onto agar containing 4 × MIC of tedizolid (data not shown); and, indeed, Shen and colleagues had to resort to prolonged serial passage under escalating tedizolid selection to recover the resistant mutant described in their study.1

  • Creating a framework to align antimicrobial resistance (AMR) research with the global guidance: a viewpoint

    by Jessica Mitchell, Alex J O’nEill, Rebecca King

    We describe here an initial analysis of national and international guidance documents on antimicrobial resistance (AMR) to propose a framework to align AMR research activities with global guidance. The framework provides a summary roadmap for core activities in AMR research and highlights the need for interdisciplinary and One Health collaboration. This analysis also revealed limitations in the current guidance, including a lack of explicit mention of some research activities highly relevant to AMR and a dearth of concrete objectives; consequently, an over-reliance on global guidance could be funnelling research efforts down a generic trajectory without regard to contextual factors. We suggest this framework be used by academics and policymakers to align AMR research and guidance. However, we recommend that deeper exploration be undertaken to fully contextualize the development of meaningful questions based on current knowledge, methodologies and gap analyses.


  • Open Access

    Sal-type ABC-F proteins: intrinsic and common mediators of pleuromutilin resistance by target protection in staphylococci

    by Merianne Mohamad, David Nicholson, Chayan Kumar Saha, Vasili Hauryliuk, Thomas A Edwards, Gemma C Atkinson, Neil A Ranson, Alex J O’nEill

    The first member of the pleuromutilin (PLM) class suitable for systemic antibacterial chemotherapy in humans recently entered clinical use, underscoring the need to better understand mechanisms of PLM resistance in disease-causing bacterial genera. Of the proteins reported to mediate PLM resistance in staphylococci, the least-well studied to date is Sal(A), a putative ABC-F NTPase that—by analogy to other proteins of this type—may act to protect the ribosome from PLMs. Here, we establish the importance of Sal proteins as a common source of PLM resistance across multiple species of staphylococci. Sal(A) is revealed as but one member of a larger group of Sal-type ABC-F proteins that vary considerably in their ability to mediate resistance to PLMs and other antibiotics. We find that specific sal genes are intrinsic to particular staphylococcal species, and show that this gene family is likely ancestral to the genus Staphylococcus. Finally, we solve the cryo-EM structure of a representative Sal-type protein (Sal(B)) in complex with the staphylococcal 70S ribosome, revealing that Sal-type proteins bind into the E site to mediate target protection, likely by displacing PLMs and other antibiotics via an allosteric mechanism.